Search

everythinglearnresearchcommunity

for

Search:↓

Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.

Tofacitinib helped regrow hair in a teen with a unique pattern of alopecia areata.

Off-label drug use can be risky and requires careful consideration to ensure patient safety.

5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.

Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.

Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.

Tofacitinib can help hair grow back in alopecia patients but hair loss might return if the dose is lowered.

Topical ruxolitinib quickly improves non-segmental vitiligo.

Older patients without prior JAK inhibitor treatment respond best to tofacitinib for alopecia areata.

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

Topical tofacitinib may help regrow hair in children with alopecia totalis.

Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.

Upadacitinib improves life quality for Alopecia Areata patients without worsening skin issues.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

Finasteride helps female-pattern hair loss.

Upadacitinib can effectively regrow hair in alopecia areata patients without worsening sarcoidosis.

ZD1839 (Iressa) causes skin and hair side effects, treatable with tretinoin cream and minocycline.

FOLFOX6 chemotherapy effectively reduces VEGF levels and improves quality of life in advanced colorectal cancer patients.

SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

Men taking 5-alpha-reductase inhibitors before or after bladder cancer diagnosis had a lower risk of dying from the disease.

Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.

New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

Oral tofacitinib successfully treated total body hair loss in one patient.

Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.

Alpha-difluoromethylornithine prevents cancer in mice but causes hair loss.

The balance between cell renewal and differentiation controls the growth of cancerous cells in mouse skin.